• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Synthetic Platelets Offer Potential Benefits for Platelet-Associated Disorders

July 20, 2012

Professor Nishit Doshi and colleagues from the University of California, Santa  Barbara, the Scripps Research Institute, and Sanford-Burnham Medical Research Institute have reported progress in developing synthetic platelets.  They synthesized platelets, imitating the size, shape, and adhesive properties, among other attributes, of mammalian platelets, and concluded that the synthetic particles were highly successful and could have major therapeutic applications.


Reference:

Doshi N, Orje JN, Molins B, Smith JW, Mitragorti S, Ruggeri ZM. Platelet Mimetic Particles for Targeting Thrombi in Flowing Blood. Adv Mater 2012.

Image Source:  Doshi N, Orje JN, Molins B, Smith JW, Mitragorti S, Ruggeri ZM. Platelet Mimetic Particles for Targeting Thrombi in Flowing Blood. Adv Mater 2012.

Filed Under

  • News
  • Platelet Transfusion

Recommended

  • Red Blood Cells Donated by Smokers Associated with Lower Increments

  • T cell Mediated Platelet Refractoriness

  • Leukoreduction Alone May Be Sufficient to Prevent Transfusion-Transmitted Cytomegalovirus Infection in Preterm Infants

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Pre-Hospital Resuscitation with Low-Titer Type O Whole Blood for Trauma Patients

  • Double-knotting Blood Storage Bag Tubing Reduces Contamination

  • Costs of Type & Screen and Crossmatch Laboratory Tests for RBCs Higher in U.S. Compared to U.K.

  • Gene Editing of HBG1 and HBG2 Promotors to Treat β-Thalassemia and Sickle Cell Disease

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley